UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): ~~October~~November 2012, 2025

~~Leap~~Cypherpunk ~~Therapeutics,~~Technologies Inc.

(Exact name of registrant as specified in its charter)

Delaware		001-37990		27-4412575
(State or Other Jurisdiction of Incorporation)		(Commission File Number)		(I.R.S. Employer Identification No.)

47 Thorndike Street, Suite B1-1
Cambridge, MA 02141

(Address of Principal Executive Office) (Zip Code)

(617) 714-0360

(Registrant’s telephone number, including area code)

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.001 per share		LPTX		The ~~NASDAQ~~Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

~~Item~~Explanatory ~~8.01 Other Events.~~Note

OnAs ~~October~~previously ~~20,~~disclosed ~~2025, Leap~~in ~~Therapeutics, Inc. (the “Company”) issued~~ a ~~press~~Current ~~release~~Report ~~announcing~~on ~~final~~Form ~~results~~8-K ~~from~~filed ~~Part B of its DeFianCe study.~~with ~~The~~the ~~final~~Securities ~~clinical~~and ~~results~~Exchange ~~were~~Commission ~~presented~~ on ~~behalf~~November ~~of the DeFianCe study investigators by Zev Wainberg~~12, MD2205, ~~Professor~~Leap ofTherapeutics, ~~Medicine~~Inc. ~~and Co-Director~~has ofchanged ~~the~~its GIname ~~Oncology~~to ~~Program~~Cypherpunk atTechnologies ~~UCLA~~Inc., effective inon aand ~~Mini~~as ~~Oral~~of ~~session~~November ~~at the European Society for Medical Oncology (ESMO) Congress 2025 in Berlin~~12, ~~Germany~~2025.

AItem ~~copy of the news release is filed with this Current Report on Form 8-K as Exhibit 99.~~1.01 ~~and~~Entry ~~incorporated~~ into ~~this~~a ~~Item~~Material ~~8.01~~Definitive ~~by reference~~Agreement.

9On November 12, 2025, Cypherpunk Technologies Inc.01 ~~Financial~~(f./k/a ~~Statements~~Leap Therapeutics, Inc.), a Delaware corporation (the “Company”), entered into a Controlled Equity OfferingSM Sales Agreement (the “Sales Agreement”) with Cantor Fitzgerald & Co. (“Cantor”), pursuant to which the Company may offer and ~~Exhibits~~sell shares of its common stock, par value $0.001 per share (the “Shares”), having an aggregate offering price of up to $200,000,000 from time to time to or through Cantor, acting as principal and/or sales agent (the “Offering”).

~~(d)~~Subject ~~Exhibits~~to the terms and conditions of the Sales Agreement, Cantor will use its commercially reasonable efforts consistent with its normal trading and sales practices, applicable state and federal law, rules and regulations, and the rules of the Nasdaq Capital Market to sell the Shares pursuant to the Offering from time to time, based upon the Company’s instructions, including any price, time or size limits specified by the Company. The Company has provided Cantor with customary indemnification and contribution rights in favor of Cantor, and Cantor will be entitled to a commission of up to 3.0% of the gross proceeds from each sale of the Shares pursuant to the Sales Agreement.

Exhibit No.		Description
99.1		Press Release, dated October 20, 2025
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

Sales of the Shares, if any, under the Sales Agreement may be made in transactions that are deemed to be “at the market offerings” as defined in Rule 415 under the Securities Act of 1933, as amended (the “Securities Act”) or by any other method permitted by law. The Company has no obligation to sell any of the Shares and may at any time suspend offers under the Sales Agreement. The Company and Cantor may each terminate the Sales Agreement at any time upon ten business days prior notice.

~~SIGNATURES~~The Shares to be sold under the Sales Agreement, if any, will be issued and sold pursuant to the Company’s shelf registration statement on Form S-3 (File No. 333-278015) as filed with the Securities and Exchange Commission on March 18, 2024 and declared effective May 9, 2024 (the “Registration Statement”). Offerings for the Shares will be made only by means of the prospectus supplement to the Registration Statement filed with the Securities and Exchange Commission on November 12, 2025.

~~Pursuant~~The toforegoing ~~the~~description ~~requirements~~ of the ~~Securities~~Sales Agreement ~~Exchange~~is ~~Act~~not complete and is qualified in its entirety by reference to the full text of ~~1934~~the Sales Agreement, ~~the~~a ~~registrant~~copy ~~has~~of ~~duly~~which ~~caused~~is ~~this~~filed ~~report~~herewith as Exhibit 1.1 to bethis ~~signed~~Current Report on ~~its~~Form ~~behalf~~8-K byand ~~the~~is ~~undersigned~~incorporated ~~hereunto~~by ~~duly~~reference ~~authorized~~herein.

	LEAP THERAPEUTICS, INC.
Date: October 20, 2025	/s/ Douglas E. Onsi
	Douglas E. Onsi
	President & CEO

The legal opinion of Morgan, Lewis & Bockius LLP relating to the Shares being offered is filed as Exhibit 5.1 to this Current Report on Form 8-K.

This Current Report on Form 8-K shall not constitute an offer to sell or a solicitation of an offer to buy any Shares, nor shall there be any sale of Shares in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.

9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.		Description
1.1		Controlled Equity Offering^SM Sales Agreement, dated November 12, 2025, by and between the Company and Cantor Fitzgerald & Co.
5.1		Opinion of Morgan, Lewis & Bockius LLP
23.1		Consent of Morgan, Lewis & Bockius LLP (included in Exhibit 5.1)
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	CYPHERPUNK TECHNOLOGIES INC.

Date: November 12, 2025	/s/ Douglas E. Onsi
	Douglas E. Onsi
	President & CEO

Filing Compare · CYPHERPUNK TECHNOLOGIES INC.